DeepMed Research

BioNTech

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Employees: 6.1K

Market Cap: $20.7B

Website: http://www.biontech.de

Introduction: BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Clinical Trials

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2

Recruiting

Conditions: Locally Advanced Breast Cancer
Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancers

Interventions: Drug: BNT327 Dose Level 1 (DL1)
Drug: BNT327 Dose Level 1 (DL2)
Drug: Paclitaxel
Drug: Carboplatin
Drug: Eribulin
Drug: Nab-placlitaxel
Drug: BNT327 Optimized Dose
Drug: Gemcitabine
Drug: BNT327 Equivalent Q3W Dose

First Posted Date: 2024-06-07

Last Posted Date: 2025-05-02

Lead Sponsor: BioNTech SE

Target Recruit Count: 70

Registration Number: NCT06449222

Locations: 🇹🇷
Gazi University Medical Faculty, Yenimahalle, Turkey
🇺🇸
Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸
Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), New Brunswick, New Jersey, United States

and more 63 locations

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Phase 2

Active, not recruiting

Conditions: Extensive-stage Small-cell Lung Cancer
Small-cell Lung Cancer

Interventions: Drug: BNT327 Dose Level 1 (DL1)
Drug: BNT327 Dose Level 2 (DL2)
Drug: Etoposide
Drug: Paclitaxel
Drug: Topotecan
Drug: Carboplatin

First Posted Date: 2024-06-07

Last Posted Date: 2025-05-01

Lead Sponsor: BioNTech SE

Target Recruit Count: 110

Registration Number: NCT06449209

Locations: 🇦🇺
Peninsula Oncology Centre, Frankston, Australia
🇹🇷
Hacettepe University Medical Faculty Oncology Hospital, Ankara, Turkey
🇹🇷
Memorial Ankara Hospital, Ankara, Turkey

and more 62 locations

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Phase 3

Not yet recruiting

Conditions: Endometrial Cancer

Interventions: Drug: BNT323/DB-1303
Drug: Doxorubicin
Drug: Paclitaxel

First Posted Date: 2024-04-01

Last Posted Date: 2025-04-10

Lead Sponsor: BioNTech SE

Target Recruit Count: 504

Registration Number: NCT06340568

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Phase 3

Completed

Conditions: Influenza
COVID-19

Interventions: Biological: Licensed influenza vaccine
Biological: COVID-19 Vaccine
Biological: Influenza and COVID-19 Combination A
Biological: Influenza and COVID-19 Combination B
Biological: Investigational influenza vaccine
Biological: Placebo

First Posted Date: 2023-12-21

Last Posted Date: 2024-12-13

Lead Sponsor: BioNTech SE

Target Recruit Count: 8798

Registration Number: NCT06178991

Locations: 🇺🇸
Velocity Clinical Research, Cincinnati, Mt. Auburn, Cincinnati, Ohio, United States
🇺🇸
North Alabama Research Center, Athens, Alabama, United States
🇺🇸
Accel Research Sites - Birmingham Clinical Research Unit, Birmingham, Alabama, United States

and more 141 locations

Safety and Preliminary Efficacy of BNT314 with or Without an Immune Checkpoint Inhibitor in Cancer Patients with Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Tumor

Interventions: Biological: BNT314
Biological: Pembrolizumab

First Posted Date: 2023-11-29

Last Posted Date: 2024-11-27

Lead Sponsor: BioNTech SE

Target Recruit Count: 360

Registration Number: NCT06150183

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇧🇪
GZA Ziekenhuizen, Antwerpen, Belgium
🇧🇪
CHU de Liège, Liege, Belgium

and more 11 locations

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: BNT321 Dose Level 1
Drug: BNT321 Dose Level 2
Drug: mFOLFIRINOX
Drug: BNT321 RP2D

First Posted Date: 2023-10-06

Last Posted Date: 2025-01-23

Lead Sponsor: BioNTech SE

Target Recruit Count: 2

Registration Number: NCT06069778

Locations: 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
Medical University of South Carolina (MUSC), Charleston, South Carolina, United States

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Phase 1

Active, not recruiting

Conditions: Malaria

Interventions: Other: Placebo
Biological: BNT165e

First Posted Date: 2023-10-06

Last Posted Date: 2025-04-09

Lead Sponsor: BioNTech SE

Target Recruit Count: 138

Registration Number: NCT06069544

Locations: 🇺🇸
AMR Tempe, Tempe, Arizona, United States
🇺🇸
University of Maryland, Center for Vaccine Development, Baltimore, Maryland, United States
🇺🇸
AMR Las Vegas, Las Vegas, Nevada, United States

and more 2 locations

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

Phase 2

Completed

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Biological: BNT162b2 (Omi XBB.1.5)
Biological: BNT162b2 (Omi JN.1)
Biological: BNT162b2 (Omi KP.2)

First Posted Date: 2023-08-18

Last Posted Date: 2025-03-28

Lead Sponsor: BioNTech SE

Target Recruit Count: 1051

Registration Number: NCT05997290

Locations: 🇺🇸
North Alabama Research Center, Athens, Alabama, United States
🇺🇸
Medical Affiliated Research Center, Huntsville, Alabama, United States
🇺🇸
Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States

and more 29 locations

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Phase 1

Active, not recruiting

Conditions: Monkeypox

Interventions: Biological: BNT166a

First Posted Date: 2023-08-14

Last Posted Date: 2025-03-13

Lead Sponsor: BioNTech SE

Target Recruit Count: 96

Registration Number: NCT05988203

Locations: 🇺🇸
California Research Foundation, San Diego, California, United States
🇺🇸
Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States

and more 4 locations

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

Phase 1

Withdrawn

Conditions: COVID-19

Interventions: Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose

First Posted Date: 2022-11-29

Last Posted Date: 2024-03-18

Lead Sponsor: BioNTech SE

Registration Number: NCT05630352

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy